Visceral Fat in Women: Risks and Reduction

Visceral fat in women is a clinically important topic that goes well beyond appearance or overall body weight. Unlike subcutaneous fat, visceral fat sits deep within the abdominal cavity, surrounding vital organs, and releases inflammatory chemicals that directly affect metabolic health. Women face unique risks due to hormonal changes across the lifespan, particularly around the menopause, when fat distribution shifts towards the abdomen even without weight gain. Understanding what drives visceral fat, how to measure it, the health risks it carries, and what women can do about it is essential for informed, proactive healthcare decisions.

What is visceral fat and why does it affect women differently?

Visceral fat is deep abdominal fat that releases inflammatory chemicals into the portal circulation; women are disproportionately affected after the menopause, when falling oestrogen shifts fat storage from the hips to the abdomen.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it behaves differently from the subcutaneous fat found just beneath the skin. Unlike subcutaneous fat, visceral fat releases inflammatory chemicals and hormones, including cytokines and free fatty acids, directly into the portal circulation, which means it has a more immediate effect on metabolic health.^[1]

Women are affected by visceral fat in ways that differ from men, largely because of hormonal influences across the lifespan. Before the menopause, oestrogen tends to direct fat storage towards the hips and thighs (a so-called gynoid pattern), which is metabolically less harmful. After the menopause, falling oestrogen levels shift fat distribution towards the abdomen, increasing visceral fat accumulation even when overall body weight remains stable. This is why postmenopausal women face a notably higher risk of metabolic complications than premenopausal women of similar weight.

Polycystic ovary syndrome (PCOS) is another condition that disproportionately affects women and is associated with insulin resistance, which promotes visceral fat deposition.^[9] Stress and poor sleep, both of which raise cortisol levels, also encourage visceral fat accumulation. Some studies suggest women may be more sensitive to cortisol-driven fat redistribution than men, though the evidence on this specific point is not yet definitive.

Ethnicity also influences risk: women from South Asian, Black African and some other ethnic backgrounds may face higher cardiometabolic risk at lower BMI and waist measurements than white European women, which is relevant to how risk thresholds are interpreted in UK clinical practice.^[5][6]

Understanding these sex-specific mechanisms is important because it means that standard weight-based measures can underestimate metabolic risk in women, particularly those who are postmenopausal or have hormonal conditions. A woman can have a normal body mass index (BMI) and still carry a clinically significant amount of visceral fat.

How do you know if you have too much visceral fat?

A waist circumference of 80 cm or above in women signals increased health risk, with 88 cm or above indicating substantially higher risk; waist circumference is more reliable than BMI alone for detecting excess visceral fat.

Waist circumference is the most practical clinical indicator of excess visceral fat. The World Health Organization (WHO) identifies a waist measurement of 80 cm (31.5 inches) or above in women as a threshold associated with increased health risk, with 88 cm (34.5 inches) or above indicating substantially higher risk. These thresholds are also reflected in UK clinical guidance. Measuring at the midpoint between the lower rib and the top of the hip bone, after a gentle exhale, gives the most reliable result. The NHS provides guidance on how to measure your waist correctly.

It is important to note that these thresholds are derived largely from studies in white European populations. Women from South Asian, Black African and some other ethnic groups may face elevated cardiometabolic risk at lower waist measurements, and clinicians should take ethnicity into account when interpreting results.^[5][6]

Waist-to-hip ratio is a complementary measure. A ratio above 0.85 in women is considered high by the WHO and suggests central adiposity. Waist-to-height ratio, where a waist measurement greater than half the person's height is considered elevated, is increasingly used in research and clinical settings because it accounts for differences in stature, and NICE guidance on obesity identification and classification supports its use alongside BMI.^[5][6]

BMI alone is a poor proxy for visceral fat. A woman with a BMI in the healthy range can still carry excess visceral fat, particularly after the menopause, while a woman with a higher BMI may store proportionally more fat subcutaneously. This is why clinicians are encouraged to use waist circumference alongside BMI rather than relying on BMI in isolation.

Imaging techniques such as computed tomography (CT) and magnetic resonance imaging (MRI) can quantify visceral fat precisely, but these are research tools rather than routine clinical investigations. Dual-energy X-ray absorptiometry (DEXA) scanning can also estimate body composition and is available in some NHS and private settings. For most people, waist circumference measured consistently over time remains the most accessible and actionable indicator.

What health risks does visceral fat carry for women?

Excess visceral fat independently raises the risk of type 2 diabetes, cardiovascular disease, MASLD and certain cancers, even after adjusting for overall body weight.

Excess visceral fat in women is independently associated with an increased risk of type 2 diabetes, cardiovascular disease, certain cancers and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), even after adjusting for overall body weight.^[1][9] The metabolic activity of visceral fat, including its release of inflammatory mediators and its contribution to insulin resistance, is central to these risks.

Cardiovascular risk is particularly significant. Visceral fat promotes dyslipidaemia (raised triglycerides and reduced HDL cholesterol), hypertension and chronic low-grade inflammation, all of which are established cardiovascular risk factors. Postmenopausal women lose the relative cardiovascular protection associated with oestrogen at the same time as visceral fat tends to increase, creating a compounding effect on risk.

Type 2 diabetes risk rises because visceral fat impairs insulin signalling in the liver and skeletal muscle. Women with PCOS are already at elevated risk of insulin resistance, and excess visceral fat amplifies this further. Research also links higher visceral fat to an increased risk of endometrial cancer and postmenopausal breast cancer, likely through mechanisms involving oestrogen metabolism and chronic inflammation, though the strength of evidence varies across studies.^[9]

Mental health may also be affected. Visceral fat is associated with higher levels of systemic inflammation, which has been linked in some studies to depression and cognitive decline, though causality has not been firmly established. Sleep apnoea, which is underdiagnosed in women, is more common in those with central adiposity and carries its own cardiovascular and metabolic consequences.^[16][17]

It is important to note that risk exists on a continuum. Having some visceral fat is normal and necessary; the concern arises when levels are elevated above the thresholds described in the previous section, particularly when combined with other risk factors.

How can women reduce visceral fat safely and effectively?

A combination of aerobic exercise (at least 150 minutes per week), resistance training and a moderate calorie deficit is the most evidence-based approach; visceral fat tends to be mobilised earlier than subcutaneous fat during a calorie deficit.

Visceral fat responds well to lifestyle intervention, and a combination of dietary change, aerobic exercise and resistance training is the most evidence-based approach for women seeking to reduce it. Evidence from clinical studies suggests that visceral fat tends to be mobilised earlier than subcutaneous fat during a calorie deficit, which means metabolic benefits may appear before significant changes in overall body weight or appearance.

Dietary approaches that have evidence for reducing visceral fat include:

• A moderate calorie deficit (typically around 500 kcal per day below estimated requirements), sustained over months rather than weeks. Self-directed calorie restriction is not appropriate during pregnancy or breastfeeding, if you are underweight, or if you have a current or recent eating disorder; seek clinical advice in these circumstances.

• Reducing ultra-processed foods, refined carbohydrates and added sugars

• Increasing dietary fibre from vegetables, legumes and wholegrains

• Following a Mediterranean-style eating pattern, which has been associated with reduced visceral fat in a number of studies, though the evidence base continues to develop

Physical activity is particularly effective. Aerobic exercise (such as brisk walking, cycling or swimming) at moderate to vigorous intensity for at least 150 minutes per week, in line with UK Chief Medical Officers' physical activity guidelines, is associated with reductions in visceral fat.^[10][11] Some evidence suggests this effect occurs independently of overall weight loss, though the two often occur together. Resistance training preserves lean muscle mass, which supports metabolic rate, and is especially important for postmenopausal women experiencing muscle loss.

Sleep and stress management are often overlooked but clinically relevant. Chronic sleep deprivation and elevated cortisol both promote visceral fat accumulation. Aiming for seven to nine hours of sleep per night and addressing sources of chronic stress through evidence-based approaches such as cognitive behavioural therapy or mindfulness can support fat reduction.

For women who have not achieved sufficient benefit from lifestyle measures alone, a clinician may consider pharmacological options in line with NICE criteria. Weight-loss pharmacotherapy is not appropriate in pregnancy or breastfeeding, if you are underweight, or if you have a current or recent eating disorder. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of clinically appropriate options may be considered following assessment.

When should you speak to a GP about visceral fat?

Women should see their GP if their waist circumference reaches 88 cm or above, if lifestyle changes over three to six months have not improved waist measurements, or if they have PCOS, postmenopausal fat redistribution or additional cardiometabolic risk factors.

Women should speak to their GP about visceral fat if their waist circumference is at or above the higher-risk threshold of 88 cm (as defined by the WHO), particularly if this is accompanied by other risk factors such as a family history of type 2 diabetes or cardiovascular disease, raised blood pressure, abnormal lipid levels or symptoms suggestive of PCOS. Women from South Asian, Black African and some other ethnic backgrounds may face elevated risk at lower waist measurements and should discuss this with their GP.^[5][6] A GP can arrange relevant investigations, including fasting blood glucose, HbA1c, a lipid profile and blood pressure measurement, to assess overall cardiometabolic risk.

Postmenopausal women who notice a significant change in fat distribution, even without weight gain, are encouraged to raise this with their GP. Hormonal changes at this life stage can substantially alter metabolic risk, and early assessment allows for timely intervention. Women with PCOS should discuss visceral fat as part of their ongoing management, as it is a modifiable risk factor for the long-term complications associated with the condition.

If lifestyle changes have been sustained for three to six months without meaningful improvement in waist circumference or metabolic markers, a GP review is appropriate. NICE guidance on obesity and weight management sets out criteria under which pharmacological treatment or referral to a specialist weight management service may be considered.^[6][15] Access to NHS specialist services and pharmacotherapy also depends on local Integrated Care Board (ICB) commissioning and pathways, so a GP is best placed to assess eligibility and coordinate care within your local system.

Urgent medical attention (via 999 or attendance at an emergency department) is needed for symptoms such as sudden chest pain, severe breathlessness or signs of stroke. For non-urgent concerns that cannot wait for a routine GP appointment, NHS 111 can provide advice. Suspected adverse effects from any prescribed medication should be reported to the prescribing clinician and can also be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Visceral fat and metabolic inflammation: the portal theory revisited.
2. Metabolic and Epigenetic Regulation by Estrogen in Adipocytes.
3. Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan.
4. Metabolic Syndrome and Menopause: Pathophysiology, Clinical and Diagnostic Significance.
5. NG246 Overweight and obesity management: Identifying and assessing overweight, obesity and central adiposity.
6. NG246 Overweight and obesity management.
7. Calculate your waist to height ratio.
8. Overweight and obesity in adults.
9. The midlife transition and the risk of cardiovascular disease and cancer Part I: magnitude and mechanisms.
10. Physical activity guidelines: UK Chief Medical Officers' report.
11. Physical activity guidelines for adults aged 19 to 64.
12. Aerobic Exercise and Weight Loss in Adults: A Systematic Review and Dose-Response Meta-Analysis.
13. A dose-response relation between aerobic exercise and visceral fat reduction.
14. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials.
15. NG246 Overweight and obesity management: Discussing results and referral.
16. Guideline scope: Obstructive sleep apnoea/hypopnoea syndrome.
17. The relationship between obesity and obstructive sleep apnoea.

Frequently Asked Questions